166089-33-4
166089-33-4 structure
- Name: Nagrestipen
- Chemical Name: Nagrestipen
- CAS Number: 166089-33-4
- Molecular Formula: C338H516N88O108S4
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2018-07-15 22:07:39
- Modify Date: 2025-08-23 17:55:51
-
Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis[1].
| Name | Nagrestipen |
|---|
| Description | Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Nagrestipen (ECI 301) (i.v; 2 μg; daily for 5 days) significantly inhibits tumor growth at 6 Gy local irradiation of tumor sites and enhances the distant septal effect of radiation in male BALB/c mice[1]. Nagrestipen (ECI 301) (i.v; 0.08, 0.4, 2 μg; day 1,8,15) can inhibit tumor growth in a dose-dependent manner at both irradiated and unirradiated sites of female C57BL/6 with LLC cells[1]. Animal Model: Male BALB/c mice with Colon26 cells and MethA cells[1] Dosage: 2 μg Administration: Intravenous injection; daily for 5 days Result: Significantly inhibited tumor size without significant toxicity. Stopped tumor growth in the colon not only at the irradiated site but also at the unirradiated. |
| Molecular Formula | C338H516N88O108S4 |
|---|